Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease
David Choi, Nathaniel A. Cohen, Tenzin Choden, Russell D. Cohen, David T. Rubin
Abstract
Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.
Topics & Concepts
Inflammatory bowel diseaseMedicinePrior authorizationCurrent (fluid)Intensive care medicineDiseaseInternal medicinePharmacologyElectrical engineeringEngineeringInflammatory Bowel DiseaseHealth Systems, Economic Evaluations, Quality of LifeMicroscopic Colitis